- Home
- WEC vs ZTS Comparison
WEC vs ZTS Comparison
Compare WEC & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEC | ZTS |
|---|---|---|
| Founded | 1896 | 1952 |
| Country | United States | United States |
| Employees | N/A | 14500 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3B | 31.2B |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WEC | ZTS |
|---|---|---|
| Price | $109.79 | $77.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $120.08 | ★ $154.18 |
| AVG Volume (30 Days) | 1.6M | ★ 7.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.33% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | ★ 4.81 | 1.42 |
| Revenue | ★ $9,800,100,000.00 | $9,467,000,000.00 |
| Revenue This Year | $5.63 | $5.63 |
| Revenue Next Year | $6.58 | $4.77 |
| P/E Ratio | ★ $22.73 | $52.25 |
| Revenue Growth | ★ 13.96 | 2.28 |
| 52 Week Low | $102.49 | $73.82 |
| 52 Week High | $119.62 | $172.23 |
Technical Indicators
Market Signals| Indicator | WEC | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 21.17 |
| Support Level | $109.33 | N/A |
| Resistance Level | $111.52 | $129.32 |
| Average True Range (ATR) | 1.84 | 3.56 |
| MACD | -0.58 | -3.07 |
| Stochastic Oscillator | 7.96 | 8.96 |
Price Performance
Historical ComparisonAbout WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy, and 2% LNG distribution and generation.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.